TR201904662T4 - Anti-fxı antikorları ve kullanma yöntemleri. - Google Patents

Anti-fxı antikorları ve kullanma yöntemleri. Download PDF

Info

Publication number
TR201904662T4
TR201904662T4 TR2019/04662T TR201904662T TR201904662T4 TR 201904662 T4 TR201904662 T4 TR 201904662T4 TR 2019/04662 T TR2019/04662 T TR 2019/04662T TR 201904662 T TR201904662 T TR 201904662T TR 201904662 T4 TR201904662 T4 TR 201904662T4
Authority
TR
Turkey
Prior art keywords
fxi
monoclonal antibodies
antibodies
patent application
fxiia
Prior art date
Application number
TR2019/04662T
Other languages
English (en)
Inventor
Gruber Andras
I Tucker Erik
Gailani David
Original Assignee
Gruber Andras
Gailani David
I Tucker Erik
Univ Oregon Health & Science
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruber Andras, Gailani David, I Tucker Erik, Univ Oregon Health & Science, Univ Vanderbilt filed Critical Gruber Andras
Publication of TR201904662T4 publication Critical patent/TR201904662T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bu patent başvurusunda, faktör XI (fXI) için spesifik olan ve faktör XIIa (fXIIa) ile fXI aktivasyonunu önleyen monoklonal antikorlar açıklanmaktadır. Bu monoklonal antikorlar, test edilen tüm memeli türlerini bağlama kabiliyeti bulunan evrensel fXI antikorlarıdırlar. Anti-fXI monoklonal antikorları, memeli plazmalarında pıhtılaşma süresini uzatırlar. Ayrıca, bu patent başvurusunda açıklanan fXI monoklonal antikorlarının uygulanması, trombozun hayvan modellerinde, trombozun hemostazı değiştirmeden inhibe edilmesiyle sonuçlanmaktadır. Dolayısıyla, bu patent başvurusunda, fXI için spesifik olan ve fXIIa ile fXI aktivasyonunu bloke eden monoklonal antikorlar, bu tür antikorları içeren bileşimler ve immünokonjügatlar ve ayrıca, bunları kullanma yöntemleri açıklanmaktadır.
TR2019/04662T 2008-12-18 2009-12-18 Anti-fxı antikorları ve kullanma yöntemleri. TR201904662T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13859008P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
TR201904662T4 true TR201904662T4 (tr) 2019-05-21

Family

ID=42317079

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04662T TR201904662T4 (tr) 2008-12-18 2009-12-18 Anti-fxı antikorları ve kullanma yöntemleri.

Country Status (15)

Country Link
US (3) US8388959B2 (tr)
EP (1) EP2373691B1 (tr)
AU (1) AU2009335643B2 (tr)
CA (1) CA2747519C (tr)
CY (1) CY1121562T1 (tr)
DK (1) DK2373691T3 (tr)
ES (1) ES2720594T3 (tr)
HR (1) HRP20190605T1 (tr)
HU (1) HUE042940T2 (tr)
LT (1) LT2373691T (tr)
PL (1) PL2373691T3 (tr)
PT (1) PT2373691T (tr)
SI (1) SI2373691T1 (tr)
TR (1) TR201904662T4 (tr)
WO (1) WO2010080623A2 (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046728A1 (en) * 2007-10-31 2016-02-18 Bioxodes Sa Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands
US8388959B2 (en) * 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
CN102600471A (zh) * 2012-02-15 2012-07-25 中国人民解放军军事医学科学院微生物流行病研究所 一种败血症治疗的靶点
US9783614B2 (en) * 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
EA201791527A1 (ru) 2015-01-02 2017-12-29 Дайэкс Корп. Биспецифические антитела против плазменного калликреина и фактора xii
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
CA3018124A1 (en) * 2016-03-23 2017-09-28 Prothix Bv Monoclonal antibodies against the active site of factor xi and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
SG10202103120UA (en) * 2016-06-14 2021-05-28 Merck Sharp & Dohme Anti-coagulation factor xi antibodies
EP3515947B1 (en) * 2016-09-20 2024-05-29 Aronora, Inc. Novel antibodies against factor xi and uses thereof
IL267538B2 (en) * 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
AU2017383537A1 (en) * 2016-12-23 2019-06-27 Novartis Ag Methods of treatment with anti-factor XI/XIa antibodies
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
BR112020010016A2 (pt) 2017-11-22 2020-11-10 Novartis Ag agentes de ligação de reversão para anticorpos antifator xi/xia e usos dos mesmos
CN114478782B (zh) * 2018-08-09 2024-04-02 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
WO2020154234A1 (en) * 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof
WO2020211674A1 (zh) 2019-04-16 2020-10-22 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
MX2022015959A (es) * 2020-07-02 2023-01-24 Beijing Tuo Jie Biopharmaceutical Co Ltd Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
EP4177275A4 (en) * 2020-07-03 2024-07-17 Suzhou Alphamab Co Ltd COAGULATION FACTOR XI (FXI)-BINDING PROTEIN
CA3235457A1 (en) 2021-10-22 2023-04-27 Regeneron Pharmaceuticals, Inc. Factor xi a2 domain-binding antibodies and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US8574849B2 (en) * 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
DK3002298T3 (da) * 2007-11-21 2019-10-28 Univ Oregon Health & Science Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
ES2702365T3 (es) 2008-06-19 2019-02-28 Prothix Bv Uso de anticuerpos antifactor XI para la prevención o el tratamiento de la formación de trombos
CA2743864A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8388959B2 (en) * 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
SG185777A1 (en) 2010-05-27 2012-12-28 Merck Sharp & Dohme Soluble guanylate cyclase activators
WO2011161099A1 (de) 2010-06-25 2011-12-29 Bayer Pharma Aktiengesellschaft Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
BR112013000596A2 (pt) 2010-07-09 2019-09-24 Bayer Intelectual Property Gmbh piridinas e tiazinas fusionadas e seus usos.
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
EP2699578B1 (de) 2011-04-21 2016-04-20 Bayer Intellectual Property GmbH Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
ES2592267T3 (es) 2011-05-06 2016-11-29 Bayer Intellectual Property Gmbh Imidazopiridinas e imidazopiridazinas sustituidas y su uso
CA2844730A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
AU2012300844B2 (en) 2011-09-02 2017-03-30 Bayer Intellectual Property Gmbh Substituted annellated pyrimidine and the use thereof
US9783614B2 (en) 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof

Also Published As

Publication number Publication date
EP2373691A4 (en) 2012-10-31
US9637550B2 (en) 2017-05-02
PL2373691T3 (pl) 2019-07-31
US8940883B2 (en) 2015-01-27
CY1121562T1 (el) 2020-05-29
SI2373691T1 (sl) 2019-05-31
DK2373691T3 (en) 2019-04-15
US20150093395A1 (en) 2015-04-02
WO2010080623A2 (en) 2010-07-15
US20130129745A1 (en) 2013-05-23
LT2373691T (lt) 2019-05-27
ES2720594T3 (es) 2019-07-23
PT2373691T (pt) 2019-05-08
AU2009335643A1 (en) 2011-07-07
CA2747519A1 (en) 2010-07-15
CA2747519C (en) 2019-04-02
WO2010080623A3 (en) 2010-11-18
EP2373691A2 (en) 2011-10-12
EP2373691B1 (en) 2019-01-23
US8388959B2 (en) 2013-03-05
HRP20190605T1 (hr) 2019-05-31
AU2009335643B2 (en) 2014-05-29
HUE042940T2 (hu) 2019-07-29
US20110250207A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
TR201904662T4 (tr) Anti-fxı antikorları ve kullanma yöntemleri.
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
PH12019501126A1 (en) Bispecific antibodies binding to coagulation factor ix and ciagulation factor x
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
NO20084878L (no) Humanisert C-kit antistoff
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
CY1118540T1 (el) Μονοκλωνικα αντισωματα
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
EA201101520A1 (ru) Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
BR112018073660A2 (pt) anticorpos anti-fator ix pádua
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
CY1117414T1 (el) Παραγοντες αναστροφης αντιπηκτικου
MX2022007465A (es) Metodos y composiciones para evaluar y tratar fibrosis.